The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil

Author:

Jansa Pavel1ORCID,Kopeć Grzegorz2,Torbicki Adam3,Sadushi‐Kolici Roela4,Campean Ioana‐Alexandra4,Halank Michael5,Simkova Iveta6,Steringer‐Mascherbauer Regina7,Salobir Barbara8,Klepetko Walter9,Lindner Jaroslav10,Lang Irene M.4

Affiliation:

1. Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital Prague Czech Republic

2. Department of Cardiac and Vascular Diseases, Pulmonary Circulation Centre Jagiellonian University Medical College and John Paul II Hospital in Krakow Krakow Poland

3. Department of Pulmonary Circulation and Thromboembolic Diseases European Health Center Otwock Poland

4. Department of Internal Medicine II, Division of Cardiology Medical University of Vienna Vienna Austria

5. Department of Internal Medicine I, University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany

6. Department of Cardiology and Angiology of Medical Faculty Slovak Medical University and National Institute of Cardiovascular Diseases Bratislava Slovakia

7. Department of Internal Medicine II Ordensklinikum Linz Elisabethinen Linz Austria

8. Department of Pulmonary Diseases and Allergy Ljubljana University Medical Centre Ljubljana Slovenia

9. Department of Cardiothoracic Surgery Medical University of Vienna Vienna Austria

10. 2nd Department of Surgery—Department of Cardiovascular Surgery General University Hospital Prague Czech Republic

Abstract

AbstractChronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, and medical therapy. Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management risk score (RRS) is able to predict long‐term outcome in inoperable patients or in patients with residual PH after surgery. We performed a post hoc analysis of RRS in patients who were enrolled in the CTREPH study (NCT01416636), a randomized, double‐blind clinical trial comparing high‐dose and low‐dose subcutaneous (SC) treprostinil in patients with severe CTEPH that was classified by an interdisciplinary CTEPH team as nonoperable, or as persistent or recurrent pulmonary hypertension after PEA. Baseline mean RRS was similar in both treatment groups (8.7 in high‐dose arm vs. 8.6 in low‐dose arm), but mean RRS change from baseline to Week 24 was greater in the high‐dose treprostinil group than in the low‐dose treprostinil group (−0.88 vs. −0.17). The difference in RRS change from baseline to Week 24 between high dose versus low dose was statistically significant with mean difference of −0.70 (95% confidence interval: −1.36 to −0.05, p = 0.0352), and was driven mainly by improvement of World Health Organization functional class and N‐terminal pro‐brain natriuretic peptide concentration. SC treprostinil therapy administered in standard dose had positive effect on the risk profile measured by RRS in patients with inoperable or persistent/recurrent severe CTEPH. Although our study was limited by the small sample size and post hoc nature, assessment of risk profile is of great importance to this particular patient population with very poor prognosis.

Funder

AOP Orphan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3